vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) on haemodynamics and permanence of the perfused isolated rat kidney. Nephrol Dial Transplant 1998;13:875–85.

11. Fukumura D, Gohongi T, Kadambi A, Izuimi Y, Ang J, Yun CO, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001;98:2604–9.

12. Gerber HP, McMurray A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336–43.

13. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 1999;274:33057–63.

14. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 2002;87:4238–44.

15. Tuttle RM, Fleisher M, Francis GL, Robbins RJ. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 2002;87:1737–42.

16. Zapf J, Walter H, Froesch ER. Radioimmunological determination of insulin-like growth factors I and II in normal subjects and in patients with growth disorders and extraparenchymatic tumor hypoglycemia. J Clin Invest 1981;68:1321–30.

17. Mieli JP, Taylor AM, Zini M, Maheshwari HG, Ross RJ, Valcavi R. Effects of hypothyroidism and hypothyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. J Clin Endocrinol Metab 1993;76:950–5.

18. Valcavi R, Dieguez C, Preece M, Taylor A, Portioli I, Scanlon MF. Effect of thyroxine replacement therapy on plasma insulin-like growth factor I levels and growth hormone responses to growth hormone releasing factor in hypothyroid patients. Clin Endocrinol (Oxf) 1987;27:85–90.

19. Chernauskas SD, Turner R. Attenuation of spontaneous, nocturnal growth hormone secretion in children with hypothyroidism and its correlation with plasma insulin-like growth factor I concentrations. J Pediatr 1989;114:98–72.

20. Giustina A, Wehrenberg WB. Influence of thyroid hormones on the regulation of growth hormone secretion. Eur J Endocrinol 1995;133:646–53.

21. Tsukahara H, Gordinenko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-induced nitric oxide production by endothelial cells. Kidney Int 1994;45:598–604.

22. Haylor J, Singh I, el Nahas AM. Nitric oxide synthase inhibitor prevents vasodilatation by insulin-like growth factor I. Kidney Int 1991;39:333–5.

23. Kowalski J, Hoyer MP, Endert E, Wieling W, Wiersinga WM. Endocrine factors related to changes in total peripheral vascular resistance after treatment of thyrotropic and hypothyroid patients. Eur J Endocrinol 2001;144:339–46.

24. Giannattasio C, Rivolta MR, Failla M, Mangoni AA, Stella ML, Mancia G. Large and medium sized artery abnormalities in untreated and treated hypothyroidism. J Hypertens 1989;7:1492–8.

25. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 2002;87:1996–2000.

26. Jeckmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor, Clin Chem 2001;47:817–23.

27. Sullivan PS, McDonald TP. Thyroxine suppresses thrombocytopoiesis and stimulates erythropoiesis in mice. Proc Soc Exp Biol Med 1992;201:271–7.

28. Mamiya S, Hagiwara M, Inoue S, Hidaka H. Thyroid hormones inhibit platelet myosin and function light chain kinase. J Biol Chem 1989;264:8575–9.

29. Simon M, Grone HJ, Johren O, Kullmer J, Plate KH, Risau W, Fuchs E. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995;268:F240–50.

30. Hirschberg R, Koppie JD, Blantz RC, Tucker BJ. Effects of recombinant human insulin-like growth factor I on glomerular dynamics in the rat. J Clin Invest 1991;87:1200–6.

Genomic Sequencing of a SARS Coronavirus Isolate That Predated the Metropole Hotel Case Cluster in Hong Kong, Stephen S.C. Chim; Yu-Kwan Tong; Emily C.W. Hung; Rossa W.K. Chiu; and Y.M. Dennis Lo* (Departments of 1Chemical Pathology and 2Paediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong; * address correspondence to this author at: Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Room 38023, 1/F Clinical Sciences Bldg., 30-32 Ngan Shing St, Shatin, New Territories, Hong Kong SAR; fax 852-2194-6171, e-mail loym@cuhk.edu.hk)

The epidemic of severe acute respiratory syndrome (SARS) swept across the globe, with reported cases in more than 30 countries. As of July 11, 2003, the number of reported probable cases was 8437, with 813 deaths (1). A novel coronavirus, SARS-CoV, was promptly implicated as the causative agent (2–4). Macaques infected with SARS-CoV subsequently developed respiratory symptoms and pathology similar to SARS patients, thus fulfilling the Koch postulates (5). Efforts in sequencing the viral genome promptly followed, and the genomic sequence revealed little homology to previously characterized strains of coronaviruses (6,7). The complete genomic sequences of several SARS-CoV isolates have since been made publicly available (www.ncbi.nlm.nih.gov).

Several sequence variations exist among isolates. In general, based on these sequence variations, the majority of the isolates can be segregated into two groups: isolates that were obtained from individuals who were epidemiologically linked to and those who were not linked to the Metropole Hotel in Hong Kong (8–10). Ruan et al. (10) compared the genomic sequences of 14 SARS-CoV isolates and suggested that a haplotype comprising four nucleotide positions, namely, 9404, 17564, 22222, and 27827 [GenBank accession no. AY274119 (7)], clearly defined two distinct genotypes. Isolates that were epidemiologically linked to the Metropole Hotel cluster have the configuration T:T:T:T, as opposed to the sequence C:G:C:C seen in the unassociated strains. (Note: The usage of the DNA-based code for the designation of SARS-CoV haplotypes does not imply that this virus possesses a DNA genome.)

SARS was first reported in Guangdong Province, China, in November 2002 (11). Isolates that demonstrated the C:G:C:C haplotype were epidemiologically traceable to the early part of the epidemic (9). On the other hand, SARS was first reported in Hong Kong when a cluster of cases was noted among visitors to the Metropole Hotel. This case cluster comprised international travelers who subsequently brought SARS to other countries, including Vietnam, Canada, and Singapore (11). Epidemiologic investigations revealed that the cases were traceable to a nephrologist from Guangdong Province, China, who checked into the hotel on February 21, 2003 (8,11). These data suggest that since the emergence of SARS-CoV in

DOI: 10.1373/clinchem.2003.021022
southern China, at least two strains of the virus had emerged (9).

We recently confirmed a case of SARS that presented in Hong Kong before the report of the case cluster at the Metropole Hotel. It would be of interest to determine whether this strain is related to either of the reported groups. This patient, designated A, presented to a hospital in Hong Kong on February 17, 2003, with a 2-day history of fever, chills, rigors, dry cough, and intense malaise. She resided in the US, but before symptom onset, she had been visiting her ailing mother in Guangzhou, China. Her mother died on February 12, 2003, of a cause unknown to the family. After admission, patient A deteriorated rapidly and required intensive care. Her chest radiograph revealed patchy infiltration, and serologic testing subsequently showed markedly increased antibody titers against SARS-CoV. Four household members and two healthcare workers later developed fever and respiratory symptoms.

In view of the distinct epidemiologic history, serum samples were retrieved from patient A. Viral RNA was extracted from 280 μL of the patient’s serum with a QIAamp Viral RNA Mini Kit (Qiagen), according to the manufacturer’s instructions, and eluted in 50 μL of RNase-free water; 11 μL of viral RNA was then reverse transcribed by Superscript III (Invitrogen) with reverse primers (PCR-R) targeting regions on the SARS-CoV genome that flank 20 selected polymorphic sites. Because polymorphisms seen in a single isolate could potentially be a result of culture or sequencing artifacts, we selected the target sites based on polymorphisms that were shared by at least two SARS-CoV isolates published in GenBank at the time of this study. The product was then amplified with use of 14 pairs of forward (PCR-F) and reverse (PCR-R) primers in a cDNA polymerase mixture (BD Clontech), with initial denaturation at 95 °C for 1 min and 35 cycles of denaturation at 95 °C for 0.5 min, annealing at 55 °C for 0.5 min, and extension at 68 °C for 1.5 min, and a final extension at 68 °C for 10 min. Seminested PCR was performed with the PCR-F and BSEQ-R series of primers with the same thermal profile. Primer sequences are available in the Data Supplement accompanying the online version of this Technical Brief at http://www.clinchem.org/content/vol50/issue1/. Multiple negative PCR controls were included in each amplification.

The DNA of each amplicon was sequenced by the dyeoxy dye terminator method on an automated DNA sequencer (3100 Genetic Analyzer; Applied Biosystems) based on capillary electrophoresis. The PCR-F, ASEQ-F, BSEQ-F, ASEQ-R, and BSEQ-R series of oligonucleotides were used as sequencing primers. Sequences were edited and aligned, and comparisons were made with the SeqScape software (Applied Biosystems). Regions that revealed nucleotide substitutions were confirmed by resequencing with a combination of different primer sets to ensure the quality of the sequencing data. On the whole, the sequencing covered one-third of the virus genome (Fig. 1) and was deposited at GenBank (accession nos. AY443086 to AY443095).

In contrast to the SARS-CoV isolates sequenced to date, the viral genomic sequence obtained from patient A, CUHK-L2, revealed a haplotype configuration of T:G:C:C (Table 1), which represents a combination of the two genotypes that typify the isolates associated and those not associated with the Metropole Hotel (10). This is particularly interesting in view of the epidemiologic history of patient A. She had a history of travel to southern China, whereas her presentation clearly predated the Metropole Hotel cluster. The CUHK-L2 sequence represents the third SARS-CoV genotype directly traceable to southern China early in the course of the SARS epidemic, with a transitory sequence that bridges the two major genotypes reported earlier.

We then compared the CUHK-L2 sequence with the complete genomic sequences of other SARS-CoV isolates. We note that in addition to the four-nucleotide haplotype, the nucleotide sequences at three additional positions, 19838, 21721, and 27243 (Table 1), also distinctly segregated the isolates associated with the Metropole Hotel from the unassociated strains with the exception of CUHK-L2 and CUHK-W1 (GenBank accession no. AY278554). Although the isolates that are or are not linked to the Metropole Hotel showed a sequence of A:G:C or G:A:T, respectively, both CUHK-L2 and CUHK-W1 had a configuration that is a combination of the two haplotypes, A:A:C. CUHK-W1, as reported previously (9), was isolated from a patient who presented at approximately the same time as a major hospital outbreak in Hong Kong (10). The latter hospital outbreak was epidemiologically linked to the hotel cluster. However, similar to CUHK-L2, the CUHK-W1 isolate was obtained from a patient who had no connection with the Metropole Hotel but had been traveling in southern China before symptom onset (9).

When we used the combined haplotype consisting of all seven nucleotides (Table 1), the segregation between the genotypes linked or not linked to the Metropole Hotel became less distinctive. CUHK-L2 shares three and
CUHK-W1 shares two common nucleotide sequences with the hotel-linked isolates, whereas the remaining four nucleotides for CUHK-L2 and five nucleotides for CUHK-W1 are in common with the isolates not linked to the Metropole Hotel. Epidemiologically, CUHK-L2 and CUHK-W1 were obtained from patients who presented before or around the time of the report of the hotel cluster. Thus, there is both temporal and molecular evidence to suggest that CUHK-L2 and CUHK-W1 may represent two transitory strains of SARS-CoV that bridge the evolution between the earlier SARS-CoV strains and those that are linked to the Metropole Hotel.

These data confirm that during the early part of the epidemic, the SARS-CoV was undergoing gradual evolution. However, at present, it is uncertain whether these cumulative changes contributed to the infectivity and propagation efficiency of the SARS-CoV and, thus, the development of the SARS epidemic. It remains to be seen whether this evolutionary transition of the SARS-CoV may have implications on a possible future reemergence of SARS.

We thank Prof. Sydney Chung for support during the course of this work.

References

1. Cumulative number of reported probable cases of SARS. World Health Organization. http://www.who.int/csr/sars/country/2003_07_11/en/ (Accessed August 2003).
2. Peiris JS, Lai ST, Poon LLP, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319–25.
3. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967–76.
4. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953–66.
5. Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG, et al. Aetiology: Koch’s postulates fulfilled for SARS virus. Nature 2003;423:240.
6. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394–9.
7. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The genome sequence of the SARS-associated coronavirus. Nature 2003;423:240.
8. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977–85.
9. Tsui SKW, Chim SSC, Lo YMD, Chinese University of Hong Kong Molecular SARS Research Group. Coronavirus genomic-sequence variations and the epidemiology of the severe acute respiratory syndrome. N Engl J Med 2003;348:1977–85.
10. Ruan YJ, Wei CL, Ee AL, Vega VB, Thoreau H, Su ST, et al. Comparative full-length genome sequence analysis of 14 SARS-CoV isolates and common mutations associated with putative origins of infection. Lancet 2003;361:1779–85.
11. Update: outbreak of severe acute respiratory syndrome—worldwide, 2003. Morbid Mortal Wkly Rep 2003;52:241–8.
12. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986–94.

Table 1. Haplotype comparison of SARS CoV strains from Hong Kong and two transitory genotypes.

| Isolate | Linked to Metropole Hotel | Transitory | GenBank accession no. |
|---------|---------------------------|------------|-----------------------|
| SIN2500 | Tor2 (AY278741) | C C C C C | (AY274119) |
| CUHK-L2 | Amino acid: | Valine; | | (AY443086–AY443095) |
| CUHK-W1 | Amino acid: | Cysteine; | | (AY278554) |
| BJ01 | Noncoding | | | (AY278489) |
| BJ02 | Noncoding | | | (AY278488) |
| BJ03 | Noncoding | | | (AY278487) |
| GZ01 | Noncoding | | | (AY278490) |

References

1. Cumulative number of reported probable cases of SARS. World Health Organization. http://www.who.int/csr/sars/country/2003_07_11/en/ (Accessed August 2003).
2. Peiris JS, Lai ST, Poon LLP, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319–25.
3. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967–76.
4. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953–66.
5. Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG, et al. Aetiology: Koch’s postulates fulfilled for SARS virus. Nature 2003;423:240.
6. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394–9.
7. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The genome sequence of the SARS-associated coronavirus. Nature 2003;423:240.
8. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977–85.
9. Tsui SKW, Chim SSC, Lo YMD, Chinese University of Hong Kong Molecular SARS Research Group. Coronavirus genomic-sequence variations and the epidemiology of the severe acute respiratory syndrome. N Engl J Med 2003;348:1977–85.
10. Ruan YJ, Wei CL, Ee AL, Vega VB, Thoreau H, Su ST, et al. Comparative full-length genome sequence analysis of 14 SARS-CoV isolates and common mutations associated with putative origins of infection. Lancet 2003;361:1779–85.
11. Update: outbreak of severe acute respiratory syndrome—worldwide, 2003. Morbid Mortal Wkly Rep 2003;52:241–8.
12. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986–94.

DOI: 10.1373/clinchem.2003.025536